Malignant Melanoma | Landscape & Forecast | Disease Landscape & Forecast

Publish date: August 2019

Login to access report

Coming Soon – November 2019

Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both the resectable and metastatic settings are heavily dominated by immune checkpoint inhibitors, such as market-leading Bristol-Myers Squibb / Ono Pharmaceutical’s Yervoy and Opdivo, and Merck & Co.’s Keytruda, opportunities remain for novel agents specifically targeting the underpenetrated BRAF-wild type unresectable or metastatic setting. With the expected introduction of novel agents for later lines, the malignant melanoma treatment algorithm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.

Questions Answered:

  • How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? Will drug treatment rates increase over the forecast period?
  • What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most important and why?
  • Which drugs in late-phase development are poised to change the treatment landscape for malignant melanoma and how? What sales / uptake could these drugs secure in the malignant melanoma market?
  • What are the key drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?

Content Highlights

Geographies: United States, EU5, Japan.

Primary Research:  20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.

 Epidemiology:  Diagnosed incidence of malignant melanoma by country, segmented by disease stage and BRAF mutation status.

Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2028, segmented by brands/generics and epidemiological subpopulations.

Emerging therapies:  Phase III: 11 drugs; Phase II: 45 drugs; coverage of select preclinical and Phase I products

Product Description

Disease Landscape & Forecast  provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • August 2019
      • June 2019
      • March 2019
      • December 2018
      • October 2018
      • August 2018
      • May 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Malignant Melanoma?
        • What Factors Are Constraining the Market for Malignant Melanoma?
      • Segment-Specific Trends
        • Resectable Malignant Melanoma: Stage IIB-III
        • First-Line Unresectable or Metastatic BRAF-Mutation-Positive Malignant Melanoma
        • First-Line Unresectable or Metastatic BRAF Wild-Type Malignant Melanoma
        • Previously Treated Unresectable or Metastatic BRAF-Mutation-Positive Malignant Melanoma
        • Previously Treated Unresectable or Metastatic BRAF Wild-Type Malignant Melanoma
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Disease Pathophysiology
        • Progression of Malignant Melanoma
      • Staging and Classification
        • Classification and Staging of Malignant Melanoma
        • Histopathological and Clinical Prognostic Factors for Malignant Melanoma
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Malignant Melanoma
        • Recurrent Incident Cases on Malignant Melanoma
        • Drug-Treatable Populations of Malignant Melanoma
        • Drug-Treated Populations of Malignant Melanoma
    • Current Treatment
      • Key Findings
        • Treatment Overview
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
        • BRAF/MEK Inhibitors
        • Oncolytic Viral Therapy
        • Cytokines
        • Cytotoxic Agents
      • Medical Practice
        • Drug-Treatable Populations
        • Treatment Guidelines
        • Country-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Malignant Melanoma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Malignant Melanoma
        • Immune Checkpoint Inhibitors
        • Therapeutic Vaccines
        • T-Cell-Based Therapy
        • Intralesional Therapy
        • Angiogenesis Inhibitors
        • Cytokines
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Malignant Melanoma
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Malignant Melanoma Bibliography

Author(s): Ann-Marie Looney, M.Sc., Ph.D; Oliver Blandy

Ann-Marie Looney, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr Looney worked as a postdoctoral researcher for the National Children’s Research Centre and the Irish Centre for Fetal and Neonatal Translational Research, Ireland where her work centred on the discovery and validation of biomarkers of early childhood injury and disease, with a specific focus on early childhood obesity, neonatal brain injury and autism spectrum ; She has a in Neuroscience, a by research in molecular biology and a in clinical and translational research from University College Cork, Ireland.

Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer. Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years. Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.